A Study to achieving target blood pressure goal in hypertension through Home Blood Pressure Monitoring during initial combination therapy

Not Applicable

• Conditions: Health Condition 1: I10- Essential (primary) hypertension

• Registration Number: CTRI/2022/08/045116
• Lead Sponsor: Dr Nagaraj Desai

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 January 2023

Recruitment & Eligibility

• Status: Open to Recruitment
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

Patients meeting with following criteria to be included in the study:

1. Male or female patients, age equal or >18 to equal or <85 years.

2. Patients who have uncontrolled BP with monotherapy (SBP >140 & DBP >90 mmHg)

3. Treatment naïve patients diagnosed with stage 2 de novo hypertension as per ESC/ESH 2018 guidelines on hypertension management.

4. Patients who are prescribed combination therapy as part of routine clinical practice by the study investigator.

5. Patients willing to follow clinical study instructions and complete the patient diaries allotted to them.

6. Patients or Legally acceptable representative of patient willing to provide written informed consent for participation in the clinical study.

Exclusion Criteria

Patients meeting with following criteria to be excluded from the study:

1. Female patients who are pregnant or breast feeding.

2. Patients with known liver or kidney (patients who are diagnosed with stage 3 or more Chronic Kidney Disease) dysfunction.

3. Patients who are consuming Ayurvedic/Herbal medicines which are intended for management of hypertension.

4. Patients who are suspected of or known to have an intolerance to any of the drugs prescribed as combination therapy.

5. Presence of any other clinically significant disease or laboratory findings that in the Investigators opinion may affect the study outcomes or continued participation of patient in the study.

6. Participation in another study concurrently or within 4 weeks prior to the Screening Visit.

Study & Design

• Study Type: Observational
• Study Design: Not specified